Hubei Honch Pharmaceutical Co., Ltd established in 2007, is located at Li Shizhen Pharmaceutical Industrial Park, Qichun County, Hubei Province, which covers an area of about 20,000 square meters. Honch has been engaged in the R&D and production of innovative anti-tumor and high-end veterinary APIs, and most of them are biological fermentation products. As a high-tech enterprise, Honch obtained a number of domestic and American invention patents, and won several scientific and technological innovation awards issued by the Hubei Provincial Government. The annual R&D input of Honch is up to 6 to 10% of sales revenue, and the personnel of R&D and quality team are about 50% of Honch's staff. The products on the market are based on analyzing the competitors within the global scope, over a dozen years of investment and focus. Honch has been the global exclusive manufacturer of Ixabepilone API, the global market share of Vinorelbine tartrate API is more than 30%, and Honch is the first domestic and the second global manufacturer of Lufenuron API. Honch has cooperated with the original researchers on many products. Only when the products are produced with advantages, can Honch create value for our customers. Honch has built a steady team of like-mind and ambition over the years, passed several U.S. and FDA on-site audits, and many products have obtained domestic GMP certificates and the EU CEP certificates. Moreover, many products are successfully registered in the countries including Japan, India, and Russia. Honch regards the safety and quality system specification as its life. In order to adapt to the development of the new era, Honch will not blindly pursue the scale of the enterprise, but concentrate on tapping the potential of the products, occupying a high market share globally and meanwhile becoming a specialized, special, innovative and small-giant enterprise.

Registered Capital:  31.66 million

Registered Address:  Qichun County, Huanggang, Hubei Province, China

Company Type:  MPR

Business Scope:  Manufacturing of raw materials and intermediates (anti-tumor drugs: vinorelbine tartrate, docetaxel, vinblastine sulfate, epothilone B, capecitabine, vincristine sulfate, mitomycin, ixabepilone) , Sales; manufacturing and sales of veterinary drug intermediates (milbexime, spinosyn, tyramectin A, seramectin); goods import and export business (excluding import and export goods prohibited and restricted by the state). (Involving a licensed operation project, it can only operate after obtaining the